N

Niagen Bioscience

Advances NAD+ science; consumer products

Overview

Niagen Bioscience focuses on NAD+ science and cellular health, offering Tru Niagen and Niagen Plus consumer products, licensing nicotinamide riboside (NR) to manufacturers, and providing analytical reference standards for research labs. Its flagship ingredient, Niagen, aims to raise cellular NAD+ levels to support mitochondrial function, DNA repair, and metabolism. The company differentiates itself through a 25+-year research history, 35+ human clinical studies, 50+ patents, and partnerships with leading aging biology researchers. Its goal is to extend human healthspan by restoring NAD+ levels and enabling science-based aging interventions across pharma and wellness partnerships.

Work here?Claim your company

About Niagen Bioscience

Simplify's Rating
Why Niagen Bioscience is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcareConsumer Goods

Company Size

51-200

Company Stage

Post IPO Equity

Headquarters

Los Angeles, California

Founded

1999

Get referred to Niagen Bioscience

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 GNC and Sam's Club expanded Tru Niagen to nearly 300 locations.
  • Q2 2026 revenue reached $29.8 million, with 64.8% gross margin and profitability.
  • Mass General Brigham planning and Evotec preclinical work strengthen Niagen's 2026 pipeline credibility.

What critics are saying

  • The June 2026 $50 million ATM and $125 million shelf signal dilution pressure.
  • NB4168 remains preclinical; IND timing and rare-disease commercialization still sit years away.
  • Tru Niagen depends on supplement demand and retail partners like GNC and Sam's Club.

What makes Niagen Bioscience unique

  • Niagen Bioscience's Niagen platform spans consumer, licensing, and pharma, unlike single-channel supplement rivals.
  • The March 2026 rebrand sharpened focus around NAD+ science and Tru Niagen's premium position.
  • Its research moat includes 175+ studies, NIH/Mayo collaborations, and NB4168 composition-of-matter patents.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$57.3M

Above

Industry Average

Funded Over

9 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Wellness Program
  • Retirement savings with company match
  • Paid Time Off
  • Flexible Work Hours
  • Hybrid Work Options

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

1%
Los Angeles Biotechnology Network
Oct 8th, 2026
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at niagen Bioscience, honored with the 2026 annette dickinson trailblazer award by Radicle Science and Council ...

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at niagen Bioscience, honored with the 2026 annette dickinson trailblazer award by Radicle Science and Council for Responsible Nutrition (CRN). LOS ANGELES-(BUSINESS WIRE) - - $NAGE #Award-Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Radicle Science and Council for Responsible Nutrition (CRN) honored Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs... Click here to view original post

Los Angeles Biotechnology Network
Sep 30th, 2026
Niagen Bioscience announces Start-Up Agreement with Mass General Brigham (MGB) investigators for first-of-its-kind healthy aging clinical trial.

Niagen Bioscience announces Start-Up Agreement with Mass General Brigham (MGB) investigators for first-of-its-kind healthy aging clinical trial. LOS ANGELES-(BUSINESS WIRE) - - $NAGE #Biotech-Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most... Click here to view original post

BioPharma Watch
Sep 2nd, 2026
Niagen Bioscience to present at Longevity Investors Conference.

Niagen Bioscience to present at Longevity Investors Conference. Key Takeaway: Niagen Bioscience, Inc. (NASDAQ: NAGE) will present at the Longevity Investors Conference from September 14 to 17, 2026, in Gstaad, Switzerland. CEO Rob Fried is set to participate in a panel discussing the investment case for consumer health. This event emphasizes the company's commitment to the science of healthy aging. Market sentiment analysis. Positive factors. * Niagen Bioscience is recognized as a global authority on NAD+. * Participation in the Longevity Investors Conference highlights company visibility. * CEO Rob Fried's involvement in a key panel underscores leadership in healthy aging. LOS ANGELES-(BUSINESS WIRE)- $NAGE #Biotech-Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Longevity Investors Conference, taking place from September 14 to 17, 2026, in Gstaad, Switzerland.Niagen Bioscience CEO, Rob Fried, will participate in the Longevity Goes Mainstream: The Investment Case for Consumer Health Panel on Wednesday, September 16 Frequently asked questions. What is the Longevity Investors Conference? The Longevity Investors Conference focuses on investments in healthy aging and consumer health. When is the Longevity Investors Conference taking place? The conference will occur from September 14 to 17, 2026. Who from Niagen Bioscience will participate in the conference? CEO Rob Fried will participate in a panel discussion at the conference. What is Niagen Bioscience known for? Niagen Bioscience is recognized as a global authority on NAD+ and healthy aging.

BioPharma Watch
Aug 26th, 2026
Niagen Bioscience to present at Nasdaq X LD Micro Inaugural SF Summit.

Niagen Bioscience to present at Nasdaq X LD Micro Inaugural SF Summit. Key Takeaway: Niagen Bioscience, a leader in NAD+ research, will present at the Nasdaq X LD Micro Inaugural SF Summit on September 9, 2026. This event aims to connect 25 selected public companies with institutional investors. The presentation will showcase Niagen's commitment to healthy aging and innovation in bioscience. Market sentiment analysis. Positive factors. * Niagen Bioscience is recognized as a leader in NAD+ science. * The participation in a prestigious summit highlights the company's visibility. * Engagement with institutional investors may lead to new opportunities. LOS ANGELES-(BUSINESS WIRE)- $NAGE #Bioscience-Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, in San Francisco, CA.Nasdaq is partnering with LD Micro to host 25 curated public companies, each delivering a 15-minute presentation to a room of institutional investors within the Nas Frequently asked questions. What is the Nasdaq X LD Micro summit? It is an event where selected public companies present to institutional investors. When will Niagen Bioscience present? Niagen Bioscience will present on September 9, 2026. What is Niagen Bioscience known for? The company is recognized as a leader in NAD+ and healthy aging research. How many companies will present at the summit? A total of 25 curated public companies will present at the summit.

Happi
Aug 26th, 2026
Niagen Bioscience expands Tru Niagen retail footprint with GNC and Sam's Club.

Niagen Bioscience expands Tru Niagen retail footprint with GNC and Sam's Club. At GNC, shoppers can find Tru Niagen Beauty, a supplement designed to support skin elasticity and the appearance of hair, skin and nails. August 26, 2026 Associate Editor, Happi Tru Niagen, a leader in healthy-aging NAD-boosting supplement in the US, has expanded its retail footprint at GNC and Sam's Club. "Expanding Tru Niagen across GNC and Sam's Club strengthens our retail footprint and puts the category-leading NAD+ supplement in front of new consumer audiences," said Rob Fried, CEO of parent company Niagen Bioscience. "These partnerships reflect the growing demand for credible, science-backed healthy aging solutions." With the latest retail expansion, Tru Niagen is available in nearly 300 retail locations across 44 states combined. At GNC, shoppers can find Tru Niagen Beauty, a supplement in the US featuring Niagen (patented nicotinamide riboside or NR) designed to support skin elasticity and the appearance of hair, skin and nails, along with Tru Niagen 300-mg 30-count bottles in store and online. Sam's Club shoppers can purchase Tru Niagen 300mg 120-count bottles in store and online. Supporting cellular function and healthy aging, Tru Niagen is clinically shown to increase NAD+ levels and help sustain them over time. It's powered by Niagen (patented nicotinamide riboside, or NR), a high-quality NAD-booster. NAD+ is an essential coenzyme vital to cellular health, mitochondrial function, cellular energy production and DNA repair. Embodying high scientific and quality standards, Tru Niagen is reportedly backed by more than 45 human clinical studies, over 500 published scientific studies and more than 60 patents worldwide.

Recently Posted Jobs

Sign up to get curated job recommendations

Niagen Bioscience is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs